Anticoagulation with bivalirudin is associated with improved biocompatibility in patients supported on microaxial flow pumpsCentral MessagePerspective

Objective: To evaluate whether an institutional shift from anticoagulation with heparin to bivalirudin in Impella 5.5 patients altered bleeding or thrombotic rates, transfusion dependency, or device biocompatibility. Methods: All patients supported by an Impella 5.5 between August 2022 and December...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Michaela Asher, MPhil, Emma Morganroth, BS, Amit Iyengar, MD, MSE, Michael Catalano, MD, Cindy Song, MD, David Rekhtman, MD, Max Shin, MD, Omar Toubat, MD, PhD, Samuel Kim, MD, Alyson Brown, BA, Joyce Wald, DO, Aditya Parikh, MD, Mauer Biscotti, MD, Marisa Cevasco, MD, MPH
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2026-04-01
coleção:	JTCVS Open
Assuntos:	Impella 5.5 bivalirudin heparin MCS transplant heart failure
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2666273626001269
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!